Halozyme Therapeutics (HALO) PT Cut to $15 at Piper Jaffray
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St mixed as benchmark Treasury yields reach 5%, oil takes a pause
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Halozyme Therapeutics (HALO) Misses Q3 EPS by 2c
November 10, 2014 4:41 PM ESTHalozyme Therapeutics (NASDAQ: HALO) reported Q3 EPS of ($0.16), $0.02 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $14.6 million versus the consensus estimate of $16.5 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
... More